U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07945548) titled 'A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine Learning Approach With Real-world Data' on Nov. 12.
Brief Summary: The aim of this study is to assess key factors associated with response and non-response to the current established management algorithm for elevated liver enzymes (ELE) following ribociclib treatment in hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (aBC) patients in real world settings in the United States (US). The data for this study will be drawn from a US-based breast ca...